Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
Latest Information Update: 18 May 2022
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
- Indications Stroke; Thromboembolism; Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 04 May 2022 Status changed from active, no longer recruiting to completed.
- 11 Apr 2018 Planned End Date changed from 30 Mar 2018 to 26 Feb 2019.
- 11 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 26 Dec 2018.